AZTA vs TMO: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
TMO is the larger of the two ($249.73B market cap): the incumbent the market prices for continued execution (24.26x forward earnings, beta 0.85). AZTA is the smaller challenger ($1.87B), actually pricier on forward earnings (50.37x): more room to run, but more to prove. If you believe AZTA earns its premium (50.37x forward earnings, so the market expects more from it), AZTA fits. If you believe in paying less for profit, TMO fits at 24.26x.
AZTA vs TMO: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AZTA | TMO | What it tells you |
|---|---|---|---|
| Market cap | $1.87B | $249.73B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 50.37 | 24.26 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.47 | 0.85 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 85% of range | 82% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.34 | 4.56 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: TMO is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how AZTA and TMO affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AZTA and TMO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AZTA and TMO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Azenta (AZTA) do?
Azenta, Inc., based in Burlington, Massachusetts, is what remains of Brooks Automation after it sold its semiconductor robotics business in 2022. It now has two segments. Sample Management Solutions (about $344 million of fiscal 2026 revenue) sells automated freezers and storage systems, cryogenic equipment, sample tubes and consumables, and runs repositories that store millions of biological samples for drug companies, biobanks and research groups. Multiomics (about $277 million) is GENEWIZ, which sells Sanger sequencing, next-generation sequencing and gene synthesis as a service. In July 2026 Azenta sold B Medical Systems, its vaccine cold-chain business, so it is now reported as discontinued.
What does Thermo Fisher Scientific (TMO) do?
Thermo Fisher Scientific, headquartered in Waltham, Massachusetts, is a global provider of scientific instruments, consumables, reagents, and services used across pharmaceutical and biotech drug development, clinical diagnostics, academic research, and environmental and industrial testing. The company operates through four reportable segments: Life Sciences Solutions (reagents, proteins, and consumables for research and bioproduction), Analytical Instruments (mass spectrometers, chromatography systems, electron microscopes, and laboratory equipment), Specialty Diagnostics (clinical diagnostic kits and transplant diagnostics), and Laboratory Products and Biopharma Services (supply-chain distribution, contract research through PPD, and contract drug manufacturing through Patheon). Revenue is generated through instrument sales, high-margin consumables and reagents that customers repurchase continuously, long-term service contracts, and growing contract development and manufacturing (CDMO) fees; consumables and services collectively account for a majority of annual sales and provide durable recurring revenue.
AZTA vs TMO: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- AZTA drivers: Margin recovery from cost cuts; Gene synthesis replacing Sanger sequencing.
- TMO drivers: Bioprocessing and Biologic Drug Manufacturing Tailwind; Recurring Consumables and Reagents Engine.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Execution is the main risk. For TMO, the most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth.
AZTA or TMO: which should you pick?
If the story you believe is AZTA's (Margin recovery from cost cuts), AZTA is the more direct way to own it; if it is TMO's (Bioprocessing and Biologic Drug Manufacturing Tailwind), TMO is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AZTA and TMO guides.
AZTA vs TMO: the full fundamentals
AZTA. At ~$44.51 and roughly 43 to 44 million shares, Azenta's market value is about $1.9 billion, or about $1.4 billion after subtracting cash and securities. That is roughly 2.9 times fiscal 2026 revenue and about 2.2 times the midpoint of fiscal 2027 guidance after cash, and about 50 times the ~$0.89 of EPS analysts expect for fiscal 2027. GAAP results were a loss of $3.50 per share from continuing operations because of the impairment. Before the November report, MarketBeat showed a consensus Hold rating with an average target near $40 to $41; Yahoo Finance's five-analyst consensus now reads Buy with a mean target near $52.60, after Needham moved to $57.
TMO. Thermo Fisher trades at roughly 24 times forward earnings and ~36 times trailing GAAP earnings, which include heavy acquisition amortization, after a third quarter that beat on EPS for the fourth time running. Analysts expect 2026 adjusted EPS of ~$25.28 on ~$48.0 billion of revenue and ~$27.79 on ~$50.5 billion in 2027, roughly 10% growth each year, and the ~$757 mean target from 25 analysts sits about 12% above the November 20 price. Trailing free cash flow of ~$6.4 billion still gives the company flexibility for repurchases, dividends and acquisitions.
Headline figures (approximate, November 2026): AZTA shows revenue (fy2026, continuing ops) ~$622 million (Q4 up ~5%), fy2027 revenue guidance ~$648M to $660M, adjusted eps (fy2026 / q4) ~$0.48 / ~$0.28 vs ~$0.11 est., adjusted ebitda margin (fy2026) ~9.4%; TMO shows revenue (ttm) ~$47.4 billion; full year 2025 ~$44.6 billion, q3 2026 revenue ~$12.14 billion, up ~9% year over year, q3 2026 adjusted eps ~$6.68 vs ~$6.40 expected, margins (ttm) Gross ~41%, GAAP operating ~19%, net ~15%.
The bottom line: AZTA vs TMO
AZTA and TMO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined AZTA and TMO exposure against your real portfolio. It is not an investment adviser.
Wondering how AZTA or TMO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Azenta
Ask Walnut's AI anything about AZTA and see how it fits what you own.
FAQ
What is the difference between AZTA and TMO?
+
Azenta, Inc., based in Burlington, Massachusetts, is what remains of Brooks Automation after it sold its semiconductor robotics business in 2022. Thermo Fisher Scientific, headquartered in Waltham, Massachusetts, is a global provider of scientific instruments, consumables, reagents, and services used across pharmaceutical and biotech drug development, clinical diagnostics, academic research, and environmental and industrial testing. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AZTA or TMO the better stock?
+
Neither is universally better. TMO is the larger incumbent; AZTA is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AZTA or TMO?
+
On forward P/E (as of November 2026), AZTA trades at 50.37x and TMO at 24.26x, so TMO is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AZTA and TMO?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AZTA vs TMO?
+
AZTA: Execution is the main risk. Azenta reaffirmed growth and margin targets in February 2026, then cut them in May alongside a $149 million impairment, and the stock fell about 25%. Guidance for fiscal 2027 asks for 3% to 5% organic growth and wider margins at the same time, under an interim CEO. Several law firms, including Rosen and Pomerantz, have announced investigations into possible securities claims tied to the May guidance cut and the August CEO resignation; as of early November 2026 no filed complaint was confirmed, but one could follow. Sanger sequencing keeps shrinking, and gene synthesis is crowded, with Twist Bioscience, IDT (part of Danaher) and GenScript all larger in the market. The Elegen license and SynPlexity purchase are early bets that cut margin first. Automated Stores sales depend on customers' capital budgets and on fixing the quality problems. China drove gene synthesis growth (China revenue rose 23% in fiscal 2026), which exposes the company to US-China trade and biotech policy. Lower NIH and academic funding and slower biotech spending would also weigh on demand. After a ~20% one-day rise and a gain of about 34% over three months, the shares carry high expectations into fiscal 2027, at about 50 times forward EPS estimates of $0.89. TMO: The most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth. Thermo Fisher's active acquisition strategy carries integration and leverage risk, particularly after committing approximately $13 billion to mergers and acquisitions in 2025 alone; total debt stood near ~$41.4 billion against ~$6.1 billion of cash on the September 2026 balance sheet, and a large deal that underperforms expectations could weigh on earnings and the balance sheet simultaneously. Geopolitical friction, particularly regarding China, creates both a demand risk (softer orders from Chinese academic and industrial customers) and a supply chain risk, while tariff policy changes can disrupt cost structures. Finally, valuation risk remains: the stock trades near ~36 times trailing GAAP earnings and ~24 times forward estimates, so a slip in growth from the third quarter's ~9% pace would test a multiple that has already expanded this year.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AZTA or TMO; figures are approximate and dated (as of November 2026). Verify current data before investing.